Comparison of efficacy，safety and economics of bid-winning and original Moxifloxacin hydrochloride tablets in the treatment of outpatient community-acquired pneumonia
- VernacularTitle:中标与原研盐酸莫西沙星片治疗门诊社区获得性肺炎的有效性、安全性与经济性比较
- Author:
Jie PANG
1
,
2
;
Xiaowen WU
1
;
Chunhua LI
3
;
Taiyu JIN
4
;
Weili YOU
1
Author Information
1. Dept. of Pharmacy，Lianyungang First People’s Hospital，Jiangsu Lianyungang 222023，China
2. Dept. of Pharmacy，the First Affiliated Hospital of Kangda College of Nanjing Medical University，Jiangsu Lianyungang 222023，China
3. Dept. of Respiratory and Critical Care Medicine，Lianyungang First People’s Hospital，Jiangsu Lianyungang 222023，China
4. Dept. of Pharmacy，Lianyungang Second People’s Hospital，Jiangsu Lianyungang 222023，China
- Publication Type:Journal Article
- Keywords:
community-acquired pneumonia;
outpatient;
moxifloxacin hydrochloride;
generic drug;
original drug;
centralized
- From:
China Pharmacy
2023;34(2):200-204
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy， safety and economics of bid-winning and original Moxifloxacin hydrochloride tablets in the treatment of outpatient community-acquired pneumonia （CAP）. METHODS A retrospective cohort study was conducted to screen and include CAP outpatients during the period of January to December 2021 in Lianyungang First People’s Hospital. They were divided into generic drug group （1 058 cases） and bid-winning drug group （1 121 cases） according to the drug source. Two groups were respectively given original and bid-winning Moxifloxacin hydrochloride tablets， 0.4 g each time， once a day. The efficacy indexes （clinical effective rate， remission time， treatment course， revisiting rate） and safety indexes （allergy， nervous system symptoms， etc.） were compared between the two groups； and the influence factors of clinical treatment failure were analyzed with multi-factor modified Poisson regression model. The economic indicators of the two drugs [quantity， consumption sum， defined daily doses （DDDs）， defined daily dose cost （DDDc）， price ratio， replacement rate] were compared. RESULTS There were no significant differences in the clinical effective rate， treatment course， revisiting rate， the incidence of nervous system symptoms and Q-T interval prolongation between the two groups （P＞0.05）. The remission time of original drug group was significantly shorter than that of bid-winning drug group， and the incidence of total adverse drug reaction， allergy reaction， gastrointestinal symptom reaction and hyperglycemia were significantly lower than those in bid-winning drug group（P＜0.05）. Multivariate Poisson regression analysis showed that bid-winning drug did not increase the risk of clinical treatment failure in CAP outpatients [RR＝1.132， 95%CI （0.883， 1.542）， P＝0.327]. However， antibiotic exposure history， more than 2 items of abnormal clinical manifestations and auxiliary examination all increased the risk of clinical treatment failure （P＜0.05）. Compared with before the implementation of centralized volume-based procurement policy， the quantity and DDDs of Moxifloxacin hydrochloride tablets increased significantly， while the consumption sum decreased significantly， DDDc of bid-winning drug decreased significantly， the price ratio of it to original drug decreased to 0.117， and the replacement rate increased to 69.44% after the implementation of centralized volume- based procurement policy. CONCLUSIONS Compared with original drug， bid-winning Moxifloxacin hydrochloride tablet shows reliable efficacy and obvious price advantage in the treatment of outpatient CAP， but the incidence of adverse drug reactions is higher.
